• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Bo R. Rueda, PhD

Associate Professor, Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Associate Director, Vincent Center for Reproductive Biology, Massachusetts General Hospital

Contact Info

Bo Rueda
Massachusetts General Hospital
55 Fruit Street
Boston, MA, 02114
Mailstop: THR 901A
Phone: 617-724-2825
Fax: 617-726-0561


Ashley Cambridge
Vincent Center for Reproductive Biology/ Vincent Obstetrics and Gynecology Service
Massachusetts General Hospital
55 Fruit St
Thr 901
Boston, MA, 02114
Phone: 617-724-6047
Fax: 617-726-0561

DF/HCC Program Affiliation

Gynecologic Cancers

Lab Website

Vincent Center for Reproductive Biology

Research Abstract

Identification and functional characterization of gynecologic cancer stem cells: Recent experiments conducted by our group in collaboration with Drs. Rosemary Foster provide evidence to support the concept that both human endometrial and ovarian cancers contain a rare subpopulation of tumor-initiating cells, which have stem/progenitor like properties. We are actively optimizing strategies to better isolate these rare cells, define their stem like properties, determine how they are regulated, how their local environment may influence them, whether they are resistant to current radiation or chemotherapy and ultimately how we may target them.

Molecular interrogation of gynecologic tumors: In collaboration with Drs. Darrell Borger and A. John Iafrate of the Translational Research Laboratory (MGH Cancer Center), we have been actively developing strategies for real-time identification of novel cell signaling pathways that contribute to malignant transformation, the pathology of the disease and/or chemoresistance and recurrence in gynecologic cancers. Once identified, we are actively testing new biologics and determining their efficacy in primary ovarian and/or endometrial tumor explant models and in short-term patient cell cultures derived from primary ovarian and/or endometrial tumors.

Delineating the contribution of novel genomic mutations to the pathology of gynecologic cancers: We are currently conducting array CGH analysis of a large cohort of endometrial and ovarian gynecologic cancer samples with annotated clinical information in an attempt to detect novel mediators of malignant transformation and tumor growth, and expression with clinical response.

Defining the functional significance of mediators of cell proliferation and/or differentiation in ovarian and uterine biology: We continue to focus effort into gaining a better overall understanding of steroid and growth factor induced cell proliferation. More recently, we have been identifying and characterizing Cables 1 interacting proteins to determine their functional significance in the regulation of the cell cycle, cell proliferation, differentiation and/or apoptosis. Moreover, we are assessing whether the biochemical interactions involving Cables 1 and the corresponding functional components are altered in the presence or absence of steroids and/or growth factors.


View All Publications